Networks

• CArdiac Research Network on Aortic VAlve and heart faiLure (CARNAVAL) [Réseau de recherche cardiaque sur la valve aortique et l’insuffisance cardiaque]
• Recherche Hospitalo-Universitaire - Search Treatment and improve Outcome for Patients with Aortic Stenosis (RHU-STOPAS)

  Research Topics

• Cardiac and vascular impact of cardiovascular risk factors and of heart failure
• Endothelium-mediated regulation of vasomotor tone in pathological conditions
• Detection and treatment of cardiac dysfunction

  Composition

• 28 researchers, engineers, technicians
• 10 PhD Students, 5 master students

  Facilities

• Small laboratory animals Magnetic Resonance Imaging (MRI)

• Experimental and clinical cardiac imaging (echocardiography, tissue Doppler, MRI)

• Clinical vascular imaging (echo-tracking, tonometry)

• Experimental vascular imaging (arteriograph, myograph)

• Electron paramagnetic resonance

• Chemiluminescence

  Activity

• Research performed in Inserm U1096 Unit, concerns the evaluation of the mechanisms and the treatment of cardiovascular diseases, and especially vascular protection and improvement of cardiac contractile function. This research is transversal, and performed both in experimental model and in human.
• Regarding vascular research, our work mostly concerns the protection of vascular endothelial cells in the context of cardiovascular risk factors or cardiovascular diseases (hypertension, diabetes, myocardial infarction, heart failure etc. ). We also investigate new biotherapy approaches for stimulation of angiogenesis and vasculogenesis.
• Regarding cardiac research, our work mostly concerns the improvement of noninvasive detection of cardiac contractile dysfunction, the search for new treatments of heart failure, the study of the links between oxidative stress and heart failure, as well as the clinical evaluation of percutaneous aortic valve replacement.

  Main contributions

• Role of cytochrome P450-derived hyperpolarizing factors (EDHF) in endothelium-dependent vasodilatation in human, and consequences of its pharmacological restoration in cardio-metabolic diseases
• Endothelial protective effects and reduction of heart failure by tyrosine phosphatase 1B inhibition
• Beneficial effects of pharmacological heart rate reduction in heart failure
• Discovery and clinical evaluation of percutaneous aortic valve replacement
• Treatment of heart failure by localized slow delivery of angiogenic growth factors

  Latest publications

2016

• Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jaisser F and Ouvrard-Pascaud A. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. Hypertension 2016, 67: 717-23.
  26902493
• Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Lévy F, Henry JP, Dumesnil A, Boukhalfa I, Banquet S, Schapman D, Thuillez C, Richard V, Mulder P and Brakenhielm E. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. Circulation 2016, 133: 1484-97.
  26933083
• Maupoint J, Besnier M, Gomez E, Bouhzam N, Henry JP, Boyer O, Nicol L, Mulder P, Martinet J and Richard V. Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure. Circ Heart Fail 2016, 9: e002895.
  27059805

2015

• Lorthioir A, Joannidès R, Rémy-Jouet I, Fréguin-Bouilland C, Iacob M, Roche C, Monteil C, Lucas D, Renet S, Audrézet MP, Godin M, Richard V, Thuillez C, Guerrot D and Bellien J. Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. Kidney Int 2015, 87: 465-72.
  25029430

2014

• Benhamou Y, Bellien J, Armengol G, Brakenhielm E, Adriouch S, Iacob M, Remy-Jouet I, Le Cam-Duchez V, Monteil C, Renet S, Jouen F, Drouot L, Menard JF, Borg JY, Thuillez C, Boyer O, Levesque H, Richard V and Joannidès R. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol 2014, 66: 3210-20.
  25047402
• Besnier M, Galaup A, Nicol L, Henry JP, Coquerel D, Gueret A, Mulder P, Brakenhielm E, Thuillez C, Germain S, Richard V and Ouvrard-Pascaud A. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice. FASEB J 2014
  24760754
• Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V and Tamion F. Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality. Arterioscler Thromb Vasc Biol 2014
  24578383

2012

• Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, Vendeville C, Dreano Y, Mercier A, Thuillez C and Joannides R. Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation 2012, 125: 1266-75.
  22412088
• Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetche D, Carrié D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, Men. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012, 366: 1705-15.
  22551129

2011

• Banquet S, Gomez E, Nicol L, Edwards-Lévy F, Henry JP, Cao R, Schapman D, Dautreaux B, Lallemand F, Bauer F, Cao Y, Thuillez C, Mulder P, Richard V and Brakenhielm E. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124: 1059-69.
  21824923

  Other Scientific Productions

• WO2020058201 - UTILISATION D'INHIBITEURS DE L'ACTIVITÉ PHOSPHATASE D'ÉPOXYDE SOLUBLE POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES
• WO2012119980 - PARTICULES CONTENANT UN FACTEUR DE CROISSANCE, ET UTILISATIONS DE CELLES-CI
• WO2018178253 - COMPOSITIONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE LA CALCIFICATION CARDIOVASCULAIRE
• WO2020178441 - INHIBITEURS DE PROTÉINE NGAL